Human PXN knockout HeLa cell line
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 4
Sanger Seq - PXN knockout HeLa
WB - PXN knockout HeLa
WB - PXN knockout HeLa
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Cell line: HeLa
Number of cells: 1x106 cells/vial, 1 mL
Cell type: Epithelial
Tissue type: Cervix
Disease: Adenocarcinoma
Organism: Human
Gender: Female
Antibiotic resistance: Puromycin 1 µg/ml
Adherent: Yes
STR analysis: Amelogenin X D5S818: 11, 12 D13S317: 12, 13.3 D7S820: 8, 12 D16S539: 9, 10 vWA: 16, 18 TH01: 7 TPOX: 8,12 CSF1PO: 9, 10
Passage number: <20
Biosafety level: 2
Viability: ~90%
Mycoplasma free: Yes
Storage: Shipped on dry ice. Store in liquid nitrogen.
Buffer constituents: 8.7% DMSO, 2% cellulose, methyl ether
Using CRISPR gene-editing to speed the preclinical pipeline
Since 2012, CRISPR has brought new methods to the research community to improve the accuracy and speed of preclinical development phase, and it is increasingly being adopted to accelerate the drug pipeline. With the increasing use of CRISPR to speed the drug pipeline, outsourcing can provide a more flexible supply of services with improved timelines. This application note from Abcam provides an overview of the CRISPR gene-editing timeline.
